Can Epigenetics Help Solve the Puzzle Between Concomitant Cardiovascular Injury and Severity of Coronavirus Disease...

Area of Science:

• Cardiology
• Virology
• Pharmacology
• Epigenetics

Background:

• Patients with cardiovascular disease (CVD) face the highest mortality risk from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
• SARS-CoV-2 infection disrupts host epigenetics, impacting cardiovascular system (CVS) function and structure.
• Managing COVID-19 in CVD patients presents challenges for cardiology and pharmacology.

Purpose of the Study:

• To explore the link between SARS-CoV-2 infection and epigenetic alterations affecting the cardiovascular system.
• To identify potential therapeutic targets for COVID-19-related cardiovascular damage.
• To review signaling pathways involved in COVID-19 pathophysiology and their epigenetic implications.

Main Methods:

• Review of current literature on COVID-19 pathophysiology, epigenetics, and cardiovascular implications.
• Analysis of signaling pathways affected by SARS-CoV-2.
• Discussion of epigenetic modifiers (epidrugs) as potential therapeutic agents.

Main Results:

• SARS-CoV-2 infection significantly impacts cardiovascular physiology through epigenetic modifications.
• Epigenetic dysregulation is a key factor in COVID-19-induced cardiovascular injury.
• Targeting epigenetic marks shows promise for novel antiviral therapies.

Conclusions:

• Understanding virus-induced epigenetic changes is crucial for managing COVID-19 in CVD patients.
• Epigenetic strategies may reduce SARS-CoV-2 aggressiveness and mitigate cardiovascular damage.
• Further research into epidrugs could lead to effective treatments for COVID-19-related cardiovascular complications.